Larimar Therapeutics, Inc. Common Stock (LRMR)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 71
- Market Cap
- $426M
About Larimar Therapeutics, Inc. Common Stock
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
SentiSense also tracks daily options readings for Larimar Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Larimar Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.